Vasculitis & polymyalgia rheumatica
Serum syndecan1 has the potential to reflect activity at diagnosis and predict death during follow-up in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis
Authors' conclusion
Serum syndecan1 at diagnosis may not only reflect AAV activity at diagnosis but may also be associated with all-cause mortality during follow-up.
Study context
- Population
- Korean patients diagnosed with AAV
- Participants
- 79 patients
- Exposure
- Serum syndecan1 levels at diagnosis vs AAV activity and all-cause mortality
- Outcome
- Whether serum syndecan1 at diagnosis reflects AAV activity at diagnosis and predicts poor outcomes during follow-up
Main finding
As reported in the abstract
Serum syndecan1 at diagnosis and AAV activity and outcomes
- Serum syndecan1 at diagnosis significantly correlated with AAV activity and functional status (Birmingham vasculitis activity score (BVAS), five-factor score (FFS), SF-36 PCS, MCS, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP))
- Serum syndecan1 ≥ 76.1 ng/mL: significantly higher risk for highest tertile of BVAS at diagnosis
- Serum syndecan1 ≥ 60.0 ng/mL: significantly higher risk for upper half of BVAS at diagnosis
- Serum syndecan1 ≥ 120.1 ng/mL: significantly higher risk for all-cause mortality during follow-up and significantly lower cumulative survival
Observational data: associations, not effects.
Original publication
Serum syndecan1 has the potential to reflect activity at diagnosis and predict death during follow-up in patients with ANCA-associated vasculitis. Arthritis Res Ther. Published 20 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →